Business
NeoGenomics to Offer Mobile Phlebotomy Services for Liquid Biopsy Tests
National In-Home Blood Sample Collection Through ExamOne® and Metro Health Staffing, LLCFT MEYERS, FL / ACCESSWIRE / November 9, 2020 / NeoGenomics, Inc.
About this update from Neogenomics, Inc.
[{"type":"text","content":"National In-Home Blood Sample Collection Through ExamOne® and Metro Health Staffing, LLCFT MEYERS, FL / ACCESSWIRE / November 9, 2020 / NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of cancer-focused genetic testing services and global oncology contract research services, announced today the launch of a mobile phlebotomy service for its blood-based tests, including InVisionFirst®-Lung, its advanced non-small cell lung cancer liquid biopsy test, and the NeoLAB® liquid biopsy suite of tests encompassing solid tumor and hematologic cancers.This service addresses the challenges and impact of COVID-19 for patients requiring timely testing to ensure efficient diagnosis and disease progression monitoring.NeoGenomics will offer in-home mobile phlebotomy services through two phlebotomy companies, ExamOne® and Metro Health Staffing, LLC, for broad national geographic coverage to ensure tests are performed conveniently and quickly for fast results. NeoGenomics will arrange for the blood sample collection at the patient's desired location and cover the expense of the mobile phlebotomy blood service.\"We want to make the testing process easy and safe for patients by providing in-home access to our liquid biopsy tests, which deliver high-quality, advanced and timely analysis of actionable genetic mutations using a simple blood draw,\" said Douglas VanOort, NeoGenomics' Chairman and Chief Executive Officer. \"This in-home service addresses patient fears of exposure to COVID-19, and ensures the efficient continuity of care, which is so crucial in the treatment and monitoring of cancer patients.\"NeoGenomics offers a broad collection of comprehensive, targeted and single gene assays for solid tumor cancer and hematologic malignancies. Peripheral blood is an option for detection of therapeutic targets and prognostic markers, and the assays have a turnaround time of seven days or less, which can save clinicians valuable time over tissue testing in critical cases. Liquid biopsy is especially useful when tissue specimens are scarce or unattainable, as is often the case in lung cancer.Click here for a video and more information about NeoGenomics' Mobile Phlebotomy Service, or for further inquiries, please contact NeoGenomics' Client Services at 1-866-776-5907.About NeoGenomics, Inc.NeoGenomics, Inc. specializes in cancer genetics testing and inf...